bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.08.02.606075

Localized in vivo prodrug activation using radionuclides

Abstract

Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof-of-principle, we tested whether this strategy of "RAdionuclide induced Drug Engagement for Release" (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing exposure to activated chemotherapy in off-target sites. MethodsWe screened the ability of radionuclides to chemically activate a model radiation-activated prodrug consisting of the microtubule destabilizing monomethyl auristatin E caged by a radiation-responsive phenyl azide ("caged-MMAE") and interpreted experimental results using the radiobiology computational simulation suite TOPAS-nBio. RAiDER was evaluated in syngeneic mouse models of cancer using fibroblast activation protein inhibitor (FAPI) agents 99mTc-FAPI-34 and 177Lu-FAPI-04, the prostate-specific membrane antigen (PSMA) agent 177Lu-PSMA-617, combined with caged-MMAE or caged-exatecan. Biodistribution in mice, combined with clinical dosimetry, estimated the relationship between radiopharmaceutical uptake in patients and anticipated concentrations of activated prodrug using RAiDER. ResultsRAiDER efficiency varied by 250-fold across radionuclides (99mTc>177Lu>64Cu>68Ga>223Ra>18F), yielding up to 1.22{micro}M prodrug activation per Gy of exposure from 99mTc. Computational simulations implicated low-energy electron-mediated free radical formation as driving prodrug activation. Clinically relevant radionuclide concentrations chemically activated caged-MMAE restored its ability to destabilize microtubules and increased its cytotoxicity by up to 600-fold compared to non-irradiated prodrug. Mice treated with 99mTc-FAPI-34 and caged-MMAE accumulated up to 3000x greater concentrations of activated MMAE in tumors compared to other tissues. RAiDER with 99mTc-FAPI-34 or 177Lu-FAPI-04 delayed tumor growth, while monotherapies did not (P<0.03). Clinically-guided dosimetry suggests sufficient radiation doses can be delivered to activate therapeutically meaningful levels of prodrug. ConclusionThis proof-of-concept study shows that RAiDER is compatible with multiple radionuclides commonly used in nuclear medicine and has the potential to improve the efficacy of radiopharmaceutical therapies to treat cancer safely. RAiDER thus shows promise as an effective strategy to treat disseminated malignancies and broadens the capability of radiopharmaceuticals to trigger diverse biological and therapeutic responses. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=136 SRC="FIGDIR/small/606075v1_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@18aef37org.highwire.dtl.DTLVardef@5f36eforg.highwire.dtl.DTLVardef@10fa0ccorg.highwire.dtl.DTLVardef@105c416_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Quintana, J., Jiang, F., Kang, M., Valladolid Onecha, V., Konik, A., Qin, L., Rodriguez, V., Hu, H., Borges, N., Khurana, I., Banla, L. I., Le Fur, M., Caravan, P., Schuemann, J., Bertolet, A., Weissleder, R., Miller, M., Ng, T.. 2024-08-06. Localized in vivo prodrug activation using radionuclides. https://doi.org/10.1101/2024.08.02.606075

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

AtomWeaver: Multi-Component Flow Matching with a Structured Geometric Prior Facilitates Non-Canonical Peptide Design

Fixed-backbone sequence discovery, or inverse folding, is a critical recurring task in the development of new polypeptide therapeutics. Once promising backbones are established for a target pocket, computational inverse folding methods greatly help accelerate generation of candidate sequences. Such methods are mature for the traditional case of limiting to the fixed twenty-letter canonical vocabulary; however, they cannot access the broader space of non-canonical amino acids (NCAAs). This design constraint is exacerbated for peptide binders, a fast-growing modality that readily incorporates NCAAs, though in practice non-canonical design frequently depends on laborious medicinal-chemistry campaigns. An extension of inverse folding to NCAAs is thus critical to accelerating design of novel therapeutic peptides. AtomWeaver uses a joint all-site, atom-level generative scheme that does not restrict side-chain categorical assignment by either predetermined or co-resolving residue identity. Conditioned only on a fixed peptide backbone and its target protein, its multi-component flow guides side-chain atoms as unlabeled points in R3 from a nested shell prior to a variable-count final atom cloud. Identity is then read by matching each predicted cloud against a reference library of canonical and non-canonical templates. Since identity is decided only at decode time, the addressable vocabulary is a property of the library rather than of the trained weights: a new NCAA costs one reference structure and no retraining, and the model can select residues it was never prompted for and never saw in training. On a deep mutational scan of two peptide-target systems, AtomWeaver's canonical readout shows high observed mean agreement with experimental values among the compared inverse-folding methods. In the mixed canonical-noncanonical setting that canonical-only baselines cannot support at all, it likewise retains ranking signal across both systems. AtomWeaver also displayed self-consistent designs on de novo binder backbones, with the highest interface confidence among compared methods. Notably, it reached these metrics while achieving broad empirical coverage of our 300-residue vocabulary, including four non-canonical types never visible in training. AtomWeaver thus serves canonical and non-canonical peptide design alike, while transforming residue vocabulary to an expandable inference-time choice.

bioengineering↗

The Influence of Obesity and Body Shape on Sagittal Plane Knee Kinematics and Kinetics during Obstacle Crossing

Altered walking mechanics in individuals with obesity can contribute to knee osteoarthritis. The gait deviations may become more pronounced during obstacle crossing. In women, body fat distribution may further influence knee load, especially when excess fat accumulates in the thighs and hips. However, relatively little is known about how regional fat distribution affects gait in women with obesity. This study investigated how obesity and, among women, different fat distributions (Apple: more abdominal fat; Pear: more lower-limb fat) influence knee biomechanics during walking with and without obstacle crossing. Participants were 15 controls without obesity (NB) and 27 with obesity (OB). Within female participants, 10 without obesity (fNB) were compared with 20 with obesity, stratified by waist-hip ratio (Apple:10, Pear:10). Speed-adjusted statistical parametric mapping applied a general linear model (NB vs. OB) and an analysis of covariance (fNB vs. Apple vs. Pear). OB exhibited a significantly greater late-stance knee extension moment than NB across all tasks, and this difference persisted among fNB, Apple, and Pear in obstacle tasks (p<0.05). OB walked with reduced knee flexion during the early-stance leading limb after crossing a medium-height obstacle (p=0.048) and a high-height obstacle (p=0.008) compared to NB. There were significant body-shape effects (p<0.05), and post-hoc comparisons confirmed that Pear had lower knee angles than fNB in both leading-limb conditions after crossing medium- and high-height obstacles (p=0.008 and p=0.001, respectively). These findings suggest that obstacle crossing helps illuminate how excess weight influences knee biomechanics, and how regional fat distribution modulates the degree of this alteration.

bioengineering↗

RNASeek: A Cross-Phyla Generative Foundation Model for Multipurpose RNA Modeling and Reinforcement Learning-Based Design

RNA plays central roles in regulating information flow and provides a versatile substrate for engineering biological functions. While large language models (LLMs) have transformed natural language processing and protein design, a general framework connecting RNA foundation models to functional sequence design remains limited. Here, we present RNASeek, a 1.6-billion-parameter generative foundation model built on a DeepSeek architecture and trained on a cross-phyla transcriptomic corpus for RNA sequence representation and generation. Natural-language tokens enable flexible conditional prediction and sequence design using a unified backbone. RNASeek captures species-specific transcript features and intron-exon boundaries in a zero-shot setting. We then fine-tune RNASeek to predict ribozyme self-cleavage activity and viral mRNA stability, revealing interpretable sequence features associated with function, including ribozyme loop flexibility and stem stability, as well as AU-rich motifs associated with mRNA stability. We use these functional predictors as reward models and apply Group Relative Policy Optimization (GRPO) to update the generation policy of RNASeek toward sequences with desired properties. GRPO-guided generation produces faster-cleaving ribozymes and stability-enhancing 3' UTRs while satisfying user-specified IUPAC constraints. Experimentally validated RNASeek-generated ribozymes achieve wild-type levels of activity, while RNASeek-generated 3' UTR sequences exceed the performance of the training data and benchmarked AI-generated 3' UTRs. Together, RNASeek establishes a unified pretrain-predict-optimize framework that connects learned RNA function to controllable de novo sequence design and provides a general strategy for engineering regulatory RNAs with desired properties.

bioengineering↗